Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...

The FDA has accepted under Priority Review the NDA for lenacapavir for the prevention of HIV as pre-exposure prophylaxis.

The major backer of the lenacapavir roll-out is assuring nervous researchers that they will keep their part of funding ...

Gilead Sciences has announced the European Medicines Agency’s (EMA) validation for a parallel accelerated review of ...

Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...

Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...

A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...

A revolutionary advancement in HIV prevention technology stands at a critical crossroads as recent policy decisions threaten ...

A groundbreaking injectable designed to curb the global spread of HIV is now at risk of being delayed due to Donald Trump's ...

The study, published Jan. 30 in the Journal of Antimicrobial Chemotherapy, adds to growing evidence that lenacapavir may be a powerful new tool in the global anti-HIV drug arsenal.Approximately, 1 ...

Gilead Sciences has allocated USD 200 million to potentially settle with federal prosecutors to resolve an investigation into ...

Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application submissions for lenacapavir for human immunodeficiency virus (HIV) prevention.